Inclusion Criteria:  Coronary angiography shows that at least one coronary artery has a diameter stenosis >70% (left main stem diameter stenosis>50%) Stable or unstable angina Availability for follow-up for up to 12 months  Exclusion Criteria:  Acute myocardial infarction within 48 hours Severe calcified lesions Unable to tolerate dual antiplatelet treatment (DAPT) Severe abnormal hematopoietic system, such as platelet count of < 100×109/L or > 700×109/L and white blood cell count of < 3×109/L Active bleeding or bleeding tendency Severe coexisting conditions, such as severe renal insufficiency (GFR < 60 ml/min•1.73m2), severe hepatic dysfunction [elevated ALT (glutamicpyruvic transaminase) or AST (glutamic-oxal acetic transaminase) level by more than three-fold of the normal limitation], acute or chronic heart failure (NYHA III-IV), acute infectious diseases, immune disorders, malignancy, etc. Life expectancy < 12 months Pregnancy or planning pregnancy Drug allergies or contraindications to aspirin, clopidogrel, ticagrelor, statins, contract, anticoagulant, stent, etc. Participation or planning to participate in another clinical trial during the same period Refusal to comply with the study protocol